HER2 MAMMARYSTEMCELL

The influence of Her2 status on mammary stem/progenitor cells

Coordinatore	INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL    more  Organization address address: Old Brompton Road 123 city: LONDON postcode: SW7 3RP contact info Titolo: Ms. Nome: Binoo Cognome: Rastogi Email: send email Telefono: +44 207 153 5196 Fax: +44 207 153 5534
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	0 €
EC contributo	171˙867 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IEF-2008
Funding Scheme	MC-IEF
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-10-01   -   2011-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL  Organization address address: Old Brompton Road 123 city: LONDON postcode: SW7 3RP contact info Titolo: Ms. Nome: Binoo Cognome: Rastogi Email: send email Telefono: +44 207 153 5196 Fax: +44 207 153 5534	UK (LONDON)	coordinator	171˙867.62

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'c-ERBB2/HER2 is a gene that is found overexpressed in ~25% of mammary tumours, and defines the molecular signature of one of the breast cancer subtypes: the HER2-positive tumour subtype. However, the role of the c-ErbB2 tyrosine kinase and the stem cell of origin of HER2-positive breast cancers are poorly understood. Our project aims to study the relationship between c-ErbB2 function and normal and tumour stem cells, as well as on the origin and development of HER2-positive tumours. First, we will study the effects of overexpressing c-ErbB2, or of knocking its expression down, on in vivo mouse mammary epithelial biology. Lentiviral transduction of primary mouse mammary epithelial cells combined with cleared fat pad transplantation and flow cytometric analysis of the resulting outgrowths will be used to study the role of the protein in the normal gland. Second, tumour cells will be isolated from mouse c-ErbB2/neu tumour models and limited dilution transplant assays of cell subpopulations will be used to identify tumour stem cells. Last, a Stop-Flox-Neu mouse model will be combined with transgenic mice carrying the Cre recombinase under different cell-type specific promoters to ask whether activity of c-ErbB2/neu in different subpopulations results in different tumour types with greater or lesser resemblance to human HER2-positive tumours. Identifying the origin of HER2 tumours may be critical for understanding resistance to HER2-targeted therapies as tumours of differing cellular origin may have distinct mechanisms of resistance. The knowledge of the relationships and interactions between HER2 and mammary stem/progenitor cells will be a key aspect of understanding both the role of HER2 in the normal breast and how its over-expression drives breast cancer.'